Cargando…
Bioreductive drugs and the selective induction of tumour hypoxia.
In this work tumour hypoxia is induced by physically occluding the tumour vascular supply by clamping, or by giving mice 5 mg kg-1 hydralazine. These methods have previously been shown to increase the radiobiological hypoxic fraction in tumours close to 100%. Their effectiveness in potentiating the...
Autores principales: | Bremner, J. C., Stratford, I. J., Bowler, J., Adams, G. E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971619/ https://www.ncbi.nlm.nih.gov/pubmed/2110814 |
Ejemplares similares
-
Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
por: Butler, S. A., et al.
Publicado: (1997) -
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995) -
Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
por: Bremner, J. C., et al.
Publicado: (1992) -
Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration.
por: Hodgkiss, R. J., et al.
Publicado: (1995) -
The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
por: Keohane, A., et al.
Publicado: (1990)